JP2016516706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516706A5 JP2016516706A5 JP2016501636A JP2016501636A JP2016516706A5 JP 2016516706 A5 JP2016516706 A5 JP 2016516706A5 JP 2016501636 A JP2016501636 A JP 2016501636A JP 2016501636 A JP2016501636 A JP 2016501636A JP 2016516706 A5 JP2016516706 A5 JP 2016516706A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- ring
- cycloalkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 417
- 150000001875 compounds Chemical class 0.000 claims description 148
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 119
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 92
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 87
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 84
- 125000001153 fluoro group Chemical group F* 0.000 claims description 80
- 150000003852 triazoles Chemical class 0.000 claims description 71
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 60
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 60
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 60
- 229910052739 hydrogen Inorganic materials 0.000 claims description 57
- 239000001257 hydrogen Substances 0.000 claims description 57
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 51
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 51
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims description 50
- 125000000623 heterocyclic group Chemical group 0.000 claims description 49
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 46
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 44
- 150000002431 hydrogen Chemical class 0.000 claims description 39
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 37
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 35
- 125000003342 alkenyl group Chemical group 0.000 claims description 31
- 125000000304 alkynyl group Chemical group 0.000 claims description 31
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 30
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 29
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 28
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 28
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 28
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims description 27
- 229910052731 fluorine Inorganic materials 0.000 claims description 25
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 24
- 229910052801 chlorine Inorganic materials 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 229910052794 bromium Inorganic materials 0.000 claims description 23
- 150000003536 tetrazoles Chemical class 0.000 claims description 22
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 21
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 19
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 19
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 18
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 18
- 125000004193 piperazinyl group Chemical group 0.000 claims description 17
- 125000003386 piperidinyl group Chemical group 0.000 claims description 17
- 125000002393 azetidinyl group Chemical group 0.000 claims description 16
- 125000002950 monocyclic group Chemical group 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 9
- FHLXQXCQSUICIN-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrido[3,2-d]pyrimidine Chemical compound C1=CC=C2NCNCC2=N1 FHLXQXCQSUICIN-UHFFFAOYSA-N 0.000 claims description 9
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 claims description 9
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 claims description 9
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 9
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 9
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims description 9
- -1 tetrahydropyran pteridine Chemical compound 0.000 claims description 9
- IDAICLIJTRXNER-UHFFFAOYSA-N 5,6,7,8-tetrahydropteridine Chemical compound C1=NC=C2NCCNC2=N1 IDAICLIJTRXNER-UHFFFAOYSA-N 0.000 claims description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 8
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 4
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 3
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 claims description 2
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims description 2
- 230000005778 DNA damage Effects 0.000 claims description 2
- 231100000277 DNA damage Toxicity 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000011285 therapeutic regimen Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 82
- OMRRUNXAWXNVFW-UHFFFAOYSA-N fluoridochlorine Chemical group ClF OMRRUNXAWXNVFW-UHFFFAOYSA-N 0.000 claims 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 2
- 125000003566 oxetanyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical compound C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 claims 1
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 1
- JUQAECQBUNODQP-UHFFFAOYSA-N furo[3,2-d]pyrimidine Chemical compound C1=NC=C2OC=CC2=N1 JUQAECQBUNODQP-UHFFFAOYSA-N 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical group O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 4
- 239000000203 mixture Substances 0.000 description 3
- 241000907681 Morpho Species 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- PQUGCKBLVKJMNT-UHFFFAOYSA-N SC560 Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(C(F)(F)F)=N1 PQUGCKBLVKJMNT-UHFFFAOYSA-N 0.000 description 2
- 125000004965 chloroalkyl group Chemical group 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 235000019000 fluorine Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361777816P | 2013-03-12 | 2013-03-12 | |
| US61/777,816 | 2013-03-12 | ||
| PCT/US2014/024767 WO2014159690A1 (en) | 2013-03-12 | 2014-03-12 | Dna-pk inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018092924A Division JP2018135389A (ja) | 2013-03-12 | 2018-05-14 | Ｄｎａ−ｐｋ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516706A JP2016516706A (ja) | 2016-06-09 |
| JP2016516706A5 true JP2016516706A5 (enExample) | 2017-04-13 |
| JP6360878B2 JP6360878B2 (ja) | 2018-07-18 |
Family
ID=50549437
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501636A Active JP6360878B2 (ja) | 2013-03-12 | 2014-03-12 | Ｄｎａ−ｐｋ阻害剤 |
| JP2018092924A Withdrawn JP2018135389A (ja) | 2013-03-12 | 2018-05-14 | Ｄｎａ−ｐｋ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018092924A Withdrawn JP2018135389A (ja) | 2013-03-12 | 2018-05-14 | Ｄｎａ−ｐｋ阻害剤 |
Country Status (26)
| Country | Link |
|---|---|
| US (11) | US9359380B2 (enExample) |
| EP (3) | EP3985003B1 (enExample) |
| JP (2) | JP6360878B2 (enExample) |
| KR (1) | KR102216284B1 (enExample) |
| CN (2) | CN107200749B (enExample) |
| AU (2) | AU2014244555B2 (enExample) |
| BR (1) | BR112015021888B1 (enExample) |
| CA (1) | CA2904641C (enExample) |
| CY (2) | CY1121360T1 (enExample) |
| DK (2) | DK2970218T3 (enExample) |
| ES (2) | ES2711839T3 (enExample) |
| HR (2) | HRP20211855T1 (enExample) |
| HU (2) | HUE057527T2 (enExample) |
| IL (1) | IL241330B (enExample) |
| LT (2) | LT3527563T (enExample) |
| ME (1) | ME03336B (enExample) |
| MX (1) | MX365294B (enExample) |
| PL (2) | PL3527563T3 (enExample) |
| PT (2) | PT3527563T (enExample) |
| RS (2) | RS58374B1 (enExample) |
| RU (1) | RU2676259C2 (enExample) |
| SG (1) | SG11201507203RA (enExample) |
| SI (2) | SI3527563T1 (enExample) |
| SM (2) | SMT202100687T1 (enExample) |
| TR (1) | TR201901886T4 (enExample) |
| WO (1) | WO2014159690A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61664B1 (sr) | 2012-04-24 | 2021-04-29 | Vertex Pharma | Inhibitori dna-pk |
| SI3527563T1 (sl) | 2013-03-12 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| SI3424920T1 (sl) | 2013-10-17 | 2020-08-31 | Vertex Pharmaceuticals Incorporated | Kokristali (s)-n-metil-8-(1-((2'-metil-(4,5'-bipirimidin)-6-il)amino)propan-2-il) kinolin-4-karboksamida in devterirani derivati le-teh kot inhibitorji dna-pk |
| ES2907461T3 (es) | 2015-01-20 | 2022-04-25 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos |
| WO2016116563A1 (en) * | 2015-01-23 | 2016-07-28 | Glaxosmithkline Intellectual Property Development Limited | Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis |
| US10774064B2 (en) | 2016-06-02 | 2020-09-15 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| KR20190062485A (ko) | 2016-09-27 | 2019-06-05 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법 |
| CU24560B1 (es) | 2017-01-23 | 2021-12-08 | Cadent Therapeutics Inc | N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio |
| CN107158001A (zh) * | 2017-03-29 | 2017-09-15 | 解益新 | 一种治疗哮喘的药物组合物 |
| ES2980444T3 (es) * | 2018-01-17 | 2024-10-01 | Vertex Pharma | Inhibidores de ADN-PK |
| CN111770921B (zh) * | 2018-01-17 | 2024-03-22 | 沃泰克斯药物股份有限公司 | 用于提高基因组编辑效率的喹喔啉酮化合物，组合物，方法和试剂盒 |
| US12121524B2 (en) * | 2018-01-17 | 2024-10-22 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
| AU2019366312B2 (en) | 2018-10-22 | 2025-04-24 | Novartis Ag | Crystalline forms of potassium channel modulators |
| CR20210441A (es) * | 2019-01-18 | 2022-03-11 | Astrazeneca Ab | Inhibidores de la pcsk9 y métodos de uso de los mismos |
| US11603523B2 (en) | 2019-01-18 | 2023-03-14 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| CN111909147B (zh) * | 2019-05-10 | 2021-07-20 | 山东轩竹医药科技有限公司 | Dna-pk抑制剂 |
| AU2020281332A1 (en) * | 2019-05-27 | 2021-11-04 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Dna-dependent protein kinase inhibitor |
| EP4022057A1 (en) | 2019-08-27 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of disorders associated with repetitive dna |
| US20230063457A1 (en) * | 2019-09-11 | 2023-03-02 | Andrew Ivor MINCHINTON | Dna-pk inhibiting compounds |
| EP4045506B1 (en) * | 2019-10-15 | 2025-07-23 | Aucentra Therapeutics Pty Ltd | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridin-3-yl) pyrimidin-2- amine for treating proliferative diseases and conditions |
| CN120004887A (zh) * | 2019-11-21 | 2025-05-16 | 江苏恒瑞医药股份有限公司 | 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用 |
| WO2021136462A1 (zh) * | 2019-12-31 | 2021-07-08 | 成都百裕制药股份有限公司 | 呋喃衍生物及其在医药上的应用 |
| CN113121573A (zh) * | 2019-12-31 | 2021-07-16 | 成都百裕制药股份有限公司 | 嘌呤衍生物及其在医药上的应用 |
| WO2021207186A1 (en) * | 2020-04-07 | 2021-10-14 | Mitobridge Inc. | Cd38 inhibitors |
| EP4143304A2 (en) | 2020-04-28 | 2023-03-08 | Intellia Therapeutics, Inc. | Methods of in vitro cell delivery |
| JP2023542548A (ja) * | 2020-09-24 | 2023-10-10 | オークランド ユニサービシズ リミテッド | 新規アミノピリジン及びその癌治療への使用 |
| US20240327412A1 (en) * | 2021-02-19 | 2024-10-03 | Kalvista Pharmaceuticals Limited | Factor xiia inhibitors |
| WO2022182959A1 (en) | 2021-02-26 | 2022-09-01 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9 |
| WO2022182957A1 (en) | 2021-02-26 | 2022-09-01 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/sacas9 |
| CA3213117A1 (en) * | 2021-03-10 | 2022-09-15 | adMare Therapeutics Society | 7-morpholino-l,6-naphthyridin-5-yl derivatives and pharmaceutical compositions thereof useful as dna-pk inhibitor |
| AU2022258733A1 (en) | 2021-04-17 | 2023-11-30 | Intellia Therapeutics, Inc. | Inhibitors of dna-dependent protein kinase and compositions and uses thereof |
| WO2023018637A1 (en) | 2021-08-09 | 2023-02-16 | Vertex Pharmaceuticals Incorporated | Gene editing of regulatory elements |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025049254A1 (en) * | 2023-08-25 | 2025-03-06 | Juno Therapeutics, Inc. | Pyrazolopyridine based inhibitors of dna-dependent protein kinase and compositions and application in gene editing |
| WO2025049481A1 (en) | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (175)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571506A (en) | 1989-08-14 | 1996-11-05 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aromatic oligomeric compounds useful as mimics of bioactive macromolecules |
| EP0507863A4 (en) | 1989-12-28 | 1993-07-07 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| DK0498722T3 (da) | 1991-02-07 | 1998-03-09 | Roussel Uclaf | Nye bicycliske nitrogenforbindelser substitueret med en benzylgruppe, fremgangsmåde til deres fremstilling, de opnåede nye intermediærer, deres anvendelse som lægemidler og de pharmaceutiske præparater som de indgår i |
| US6004979A (en) | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
| EP0519211A1 (de) | 1991-05-17 | 1992-12-23 | Hoechst Schering AgrEvo GmbH | Substituierte 4-Aminopyrimidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
| DE4208254A1 (de) | 1992-03-14 | 1993-09-16 | Hoechst Ag | Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid |
| AU3933493A (en) | 1992-04-24 | 1993-11-29 | E.I. Du Pont De Nemours And Company | Arthropodicidal and fungicidal aminopyrimidines |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| DE4437406A1 (de) | 1994-10-19 | 1996-04-25 | Hoechst Ag | Chinoxaline, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US5977117A (en) | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
| EP1754703A3 (en) | 1997-02-19 | 2007-02-28 | Berlex, Inc. | N-Heterocyclic derivatives as nos inhibitors |
| JPH10251255A (ja) | 1997-03-14 | 1998-09-22 | Nissan Chem Ind Ltd | アジン誘導体 |
| EP1001945B1 (en) | 1997-05-28 | 2011-03-02 | Aventis Pharmaceuticals Inc. | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES |
| DE19801598C2 (de) | 1998-01-17 | 2000-05-11 | Aventis Res & Tech Gmbh & Co | Katalytische Synthese von N-alkylierten Anilinen aus Olefinen und Anilinen |
| DE19836697A1 (de) | 1998-08-13 | 2000-02-17 | Hoechst Marion Roussel De Gmbh | Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| AU3033500A (en) | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
| CA2386218A1 (en) | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
| GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
| US6552016B1 (en) | 1999-10-14 | 2003-04-22 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| EP1255741A2 (en) | 2000-02-01 | 2002-11-13 | Cor Therapeutics, Inc. | 2- 1H]-QUINOLONE AND 2- 1H]-QUINOXALONE INHIBITORS OF FACTOR Xa |
| DK1259485T3 (da) | 2000-02-29 | 2006-04-10 | Millennium Pharm Inc | Benzamider og beslægtede inhibitorer for faktor Xa |
| US6605615B2 (en) | 2000-03-01 | 2003-08-12 | Tularik Inc. | Hydrazones and analogs as cholesterol lowering agents |
| DE10013318A1 (de) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
| US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
| WO2002020500A2 (en) * | 2000-09-01 | 2002-03-14 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| ATE346064T1 (de) | 2000-09-15 | 2006-12-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
| US20020111353A1 (en) | 2000-12-05 | 2002-08-15 | Mark Ledeboer | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| ATE354573T1 (de) | 2000-12-21 | 2007-03-15 | Vertex Pharma | ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß |
| EP1363904A1 (en) | 2001-02-02 | 2003-11-26 | Glaxo Group Limited | Pyrazoles as tgf inhibitors |
| MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| EP1373257B9 (en) | 2001-03-29 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| US6642227B2 (en) | 2001-04-13 | 2003-11-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| US20030096813A1 (en) | 2001-04-20 | 2003-05-22 | Jingrong Cao | Compositions useful as inhibitors of GSK-3 |
| AU2002308748A1 (en) | 2001-05-16 | 2002-11-25 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| US6762179B2 (en) | 2001-05-31 | 2004-07-13 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinase |
| CA2446756C (en) | 2001-06-01 | 2011-03-08 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinase |
| CA2450769A1 (en) | 2001-06-15 | 2002-12-27 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| JP4342937B2 (ja) | 2001-07-03 | 2009-10-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | ＳｒｃおよびＬｃｋタンパク質キナーゼの阻害剤としてのイソキサゾールピリミジン |
| GB0119865D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| DE60236322D1 (de) | 2001-12-07 | 2010-06-17 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
| SG159380A1 (en) | 2002-02-06 | 2010-03-30 | Vertex Pharma | Heteroaryl compounds useful as inhibitors of gsk-3 |
| US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
| US20030207873A1 (en) | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
| WO2003091246A1 (en) | 2002-04-26 | 2003-11-06 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| WO2004058753A1 (en) | 2002-05-06 | 2004-07-15 | Vertex Pharmaceuticals Incorporated | Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase |
| MXPA04011956A (es) | 2002-05-30 | 2005-03-31 | Vertex Pharma | Inhibidores de proteinas cinasas jak y cdk2. |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| PL375447A1 (en) | 2002-08-14 | 2005-11-28 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| US7419984B2 (en) | 2002-10-17 | 2008-09-02 | Cell Therapeutics, Inc. | Pyrimidines and uses thereof |
| EP1562911B1 (en) | 2002-11-01 | 2010-01-06 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
| DE60316013T2 (de) | 2002-11-04 | 2008-05-29 | Vertex Pharmaceuticals Inc., Cambridge | Heteroaryl-pyrimidinderivate als jak-inhibitoren |
| WO2004058749A1 (en) | 2002-12-18 | 2004-07-15 | Vertex Pharmaceuticals Incorporated | Benzisoxazole derivatives useful as inhibitors of protein kinases |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| WO2004072063A1 (en) | 2003-02-07 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
| WO2004083203A1 (en) | 2003-03-13 | 2004-09-30 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
| WO2004085418A2 (en) | 2003-03-24 | 2004-10-07 | Luitpold Pharmaceuticals, Inc. | Xanthones, thioxanthones and acridinones as dna-pk inhibitors |
| AU2004225965A1 (en) | 2003-03-25 | 2004-10-14 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
| US6875781B2 (en) | 2003-04-04 | 2005-04-05 | Cell Therapeutics, Inc. | Pyridines and uses thereof |
| US7189724B2 (en) | 2003-04-15 | 2007-03-13 | Valeant Research And Development | Quinoxaline derivatives having antiviral activity |
| EP1678147B1 (en) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| US7244735B2 (en) | 2003-12-02 | 2007-07-17 | Vertex Pharmaceuticals Inc. | Heterocyclic protein kinase inhibitors and uses thereof |
| WO2005056547A2 (en) | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
| TW200533357A (en) | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| JP5317472B2 (ja) | 2004-03-15 | 2013-10-16 | サネシス ファーマシューティカルズ， インコーポレイテッド | Ｓｎｓ−５９５、及びその使用方法 |
| GB0405985D0 (en) | 2004-03-17 | 2004-04-21 | Novartis Forschungsstiftung | Kinase |
| JP4993604B2 (ja) | 2004-05-14 | 2012-08-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピロリルピリミジンｅｒｋプロテインキナーゼインヒビターのプロドラッグ |
| JP4449580B2 (ja) | 2004-05-31 | 2010-04-14 | 宇部興産株式会社 | ４−アラルキルアミノピリミジン誘導体及び抗菌剤 |
| ATE415397T1 (de) | 2004-06-04 | 2008-12-15 | Arena Pharm Inc | Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen |
| NZ580450A (en) | 2004-09-17 | 2011-06-30 | Vertex Pharma | Diaminotriazole Compounds Useful as Protein Kinase Inhibitors |
| WO2006044456A1 (en) | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| HN2005000795A (es) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| MX2007004480A (es) | 2004-10-15 | 2007-05-08 | Astrazeneca Ab | Quinoxalinas como inhibidores b raf. |
| US20060166936A1 (en) | 2004-10-29 | 2006-07-27 | Hayley Binch | Diaminotriazole compounds useful as inhibitors of protein kinases |
| US7517870B2 (en) | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
| AU2005316599A1 (en) | 2004-12-14 | 2006-06-22 | Vertex Pharmaceuticals Incorporated | Pyrimidine inhibitors of ERK protein kinase and uses therof |
| JP2008525461A (ja) | 2004-12-23 | 2008-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｅｒｋプロテインキナーゼの選択的阻害剤およびその使用 |
| ZA200707482B (en) | 2005-02-04 | 2008-12-31 | Senomyx Inc | Compounds comprising linked heteroaryl moieties and their use as novel umami flavour modifiers, tastants and taste enhancers for comestible compositions |
| BRPI0608934A2 (pt) | 2005-04-06 | 2010-02-17 | Irm Llc | compostos e composições contendo diarilamina, e seu uso como moduladores de receptores nucleares de hormÈnios esteróides |
| AR053358A1 (es) | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
| US20090221581A1 (en) | 2005-05-25 | 2009-09-03 | Philipp Wabnitz | Methods of treating pain |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| JP2007008045A (ja) | 2005-06-30 | 2007-01-18 | Mitsui Chemicals Inc | 光記録媒体および１ｈ−キノキサリン−２−オン誘導体 |
| EP1906967A4 (en) | 2005-07-26 | 2010-07-28 | Vertex Pharma | ABL Kinase Inhibition |
| GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| JP2009514875A (ja) | 2005-11-02 | 2009-04-09 | サイトキネティクス・インコーポレーテッド | 化学物質、組成物、および方法 |
| JP5249770B2 (ja) | 2005-11-03 | 2013-07-31 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼインヒビターとして有用なアミノピリジン |
| CA2629781A1 (en) | 2005-11-16 | 2007-05-24 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| WO2007082899A1 (en) | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
| WO2007109783A2 (en) | 2006-03-23 | 2007-09-27 | Janssen Pharmaceutica, N.V. | Substituted pyrimidine kinase inhibitors |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| WO2008008852A2 (en) | 2006-07-11 | 2008-01-17 | Emory University | Cxcr4 antagonists including heteroatoms for the treatment of medical disorders |
| TW200811134A (en) | 2006-07-12 | 2008-03-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| CA2657227A1 (en) | 2006-07-14 | 2008-01-17 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors |
| US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| CA2661307C (en) | 2006-08-22 | 2016-07-19 | Technion Research And Development Foundation Ltd. | Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (pbr) |
| EP1903038A1 (de) | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren |
| US7875603B2 (en) | 2006-09-21 | 2011-01-25 | Nova Southeastern University | Specific inhibitors for vascular endothelial growth factor receptors |
| MX2009003456A (es) | 2006-10-02 | 2009-04-14 | Irm Llc | Compuestos y composiciones como inhibidores de proteina cinasa. |
| DE102006050512A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte heterocyclische Verbindungen und ihre Verwendung |
| EP2086965B1 (en) | 2006-11-02 | 2010-02-10 | Vertex Pharmaceuticals, Inc. | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
| WO2008070661A1 (en) | 2006-12-04 | 2008-06-12 | Neurocrine Biosciences, Inc. | Substituted pyrimidines as adenosine receptor antagonists |
| DE602007007985D1 (de) | 2006-12-19 | 2010-09-02 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete aminopyrimidine |
| EP2076500A4 (en) | 2006-12-28 | 2009-12-09 | Ambrx Inc | AMINO ACIDS AND POLYPEPTIDES WITH PHENAZINE AND QUINOXALIN SUBSTITUTION |
| AU2008210266B2 (en) | 2007-01-31 | 2013-09-05 | Ym Biosciences Australia Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
| WO2008106202A1 (en) | 2007-02-27 | 2008-09-04 | Housey Gerard M | Theramutein modulators |
| CA2679884A1 (en) | 2007-03-09 | 2008-09-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
| MX2009009592A (es) | 2007-03-09 | 2009-11-10 | Vertex Pharma | Aminopiridinas utiles como inhibidores de proteinas cinasas. |
| KR20090120510A (ko) | 2007-03-09 | 2009-11-24 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 아미노피리미딘 |
| CA2682195A1 (en) | 2007-03-20 | 2008-09-25 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| DE102007015169A1 (de) | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
| CA2683785A1 (en) | 2007-04-13 | 2008-10-23 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| US7910587B2 (en) | 2007-04-26 | 2011-03-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl dipeptide hepatitis C virus inhibitors |
| AU2008247592A1 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| MX2009011811A (es) | 2007-05-02 | 2010-01-14 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasa. |
| JP5389786B2 (ja) | 2007-05-02 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害として有用なアミノピリミジン |
| EP2150255A4 (en) | 2007-05-10 | 2011-10-05 | Glaxosmithkline Llc | CHINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS |
| WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| CN101687852A (zh) | 2007-05-24 | 2010-03-31 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的噻唑类和吡唑类化合物 |
| AU2008257559B2 (en) | 2007-05-25 | 2013-10-10 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (MGLU2 receptor) |
| EP2170274A1 (en) | 2007-07-02 | 2010-04-07 | Technion Research and Development Foundation, Ltd. | Compositions, articles and methods comprising tspo ligands for preventing or reducing tobacco-associated damage |
| WO2009008991A2 (en) | 2007-07-06 | 2009-01-15 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Dna-pkcs modulates energy regulation and brain function |
| UY31232A1 (es) * | 2007-07-19 | 2009-03-02 | Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones | |
| ES2389320T3 (es) | 2007-08-01 | 2012-10-25 | Kumiai Chemical Industry Co., Ltd. | Derivado de oxopirazina y herbicida |
| WO2009042294A2 (en) | 2007-08-10 | 2009-04-02 | Burnham Institute For Medical Research | Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
| DE102007044032A1 (de) | 2007-09-14 | 2009-03-19 | Bayer Healthcare Ag | Substituierte heterocyclische Verbindungen und ihre Verwendung |
| CN101889004B (zh) | 2007-10-12 | 2014-09-10 | 阿斯利康公司 | 蛋白激酶抑制剂 |
| KR20100088150A (ko) | 2007-11-06 | 2010-08-06 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 살진균성 복소환식 아민 |
| EP2231624A4 (en) | 2007-12-21 | 2011-07-06 | Progenics Pharm Inc | TRIAZINE AND CORRESPONDING COMPOUNDS WITH ANTIVIRAL EFFECT, COMPOSITIONS AND METHOD THEREFOR |
| CA2714743C (en) | 2008-02-19 | 2017-01-17 | Janssen Pharmaceutica N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| EP2253618A1 (en) | 2008-02-27 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Compound having 6-membered aromatic ring |
| JP5618837B2 (ja) | 2008-03-05 | 2014-11-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | インスリン分泌刺激剤としてのキノキサリノン誘導体、それらを得る方法および糖尿病を治療するためのそれらの使用 |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| CA2725316A1 (en) | 2008-06-02 | 2009-12-10 | Banyu Pharmaceutical Co., Ltd. | Novel isoxazole derivative |
| BRPI0915064B8 (pt) | 2008-06-16 | 2021-05-25 | Merck Patent Gmbh | derivados de quinoxalinadiona, seus usos, e medicamentos |
| EP2138488A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
| KR20110039563A (ko) | 2008-07-23 | 2011-04-19 | 버텍스 파마슈티칼스 인코포레이티드 | 피라졸로피리딘 키나제 억제제 |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| ES2548141T3 (es) | 2008-11-20 | 2015-10-14 | Glaxosmithkline Llc | Compuestos químicos |
| WO2010065899A2 (en) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof |
| EP2376485B1 (en) | 2008-12-19 | 2017-12-06 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
| US8592415B2 (en) | 2009-02-11 | 2013-11-26 | Reaction Biology Corp. | Selective kinase inhibitors |
| JP2010111702A (ja) | 2009-02-16 | 2010-05-20 | Tetsuya Nishio | 複素環化合物、その製造法および用途 |
| WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
| AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| EP2491030B1 (en) | 2009-10-22 | 2015-07-15 | Fibrotech Therapeutics PTY LTD | Fused ring analogues of anti-fibrotic agents |
| ES2360333B1 (es) | 2009-10-29 | 2012-05-04 | Consejo Superior De Investigaciones Cientificas (Csic) (70%) | Derivados de bis (aralquil) amino y sistemas (hetero) aromaticos de seis miembros y su uso en el tratamiento de patologias neurodegenerativas, incluida la enfermedad de alzheimer |
| AU2010312365A1 (en) | 2009-10-30 | 2012-06-07 | Mochida Pharmaceutical Co.,Ltd. | Novel 3-hydroxy-5-arylisoxazole derivative |
| PE20121639A1 (es) | 2009-12-25 | 2012-12-02 | Mochida Pharm Co Ltd | Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40 |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| WO2011113512A1 (de) | 2010-03-16 | 2011-09-22 | Merck Patent Gmbh | Morpholinylchinazoline |
| TWI516264B (zh) | 2010-05-06 | 2016-01-11 | 臺北醫學大學 | 芳香醯喹啉化合物 |
| JP2011246389A (ja) * | 2010-05-26 | 2011-12-08 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体 |
| DE102010025786A1 (de) | 2010-07-01 | 2012-01-05 | Merck Patent Gmbh | Pyrazolochinoline |
| DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| GB201114051D0 (en) | 2011-08-15 | 2011-09-28 | Domainex Ltd | Compounds and their uses |
| CA2846574C (en) | 2011-08-26 | 2020-07-07 | Neupharma, Inc. | Quinoxaline sulfonamide derivates for use as kinase inhibitors |
| CN115403531A (zh) | 2011-09-14 | 2022-11-29 | 润新生物公司 | 作为激酶抑制剂的化学实体、组合物及方法 |
| EP2757885B1 (en) | 2011-09-21 | 2017-03-15 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
| US9249111B2 (en) | 2011-09-30 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-RAF kinase inhibitors |
| DE102011118830A1 (de) | 2011-11-18 | 2013-05-23 | Merck Patent Gmbh | Morpholinylbenzotriazine |
| GB201120993D0 (en) | 2011-12-06 | 2012-01-18 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| WO2013112950A2 (en) | 2012-01-25 | 2013-08-01 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| RS61664B1 (sr) | 2012-04-24 | 2021-04-29 | Vertex Pharma | Inhibitori dna-pk |
| EP2916838B1 (en) | 2012-11-12 | 2019-03-13 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| SI3527563T1 (sl) | 2013-03-12 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| SI3424920T1 (sl) | 2013-10-17 | 2020-08-31 | Vertex Pharmaceuticals Incorporated | Kokristali (s)-n-metil-8-(1-((2'-metil-(4,5'-bipirimidin)-6-il)amino)propan-2-il) kinolin-4-karboksamida in devterirani derivati le-teh kot inhibitorji dna-pk |
-
2014
- 2014-03-12 SI SI201431922T patent/SI3527563T1/sl unknown
- 2014-03-12 US US14/205,508 patent/US9359380B2/en active Active
- 2014-03-12 EP EP21192836.1A patent/EP3985003B1/en active Active
- 2014-03-12 WO PCT/US2014/024767 patent/WO2014159690A1/en not_active Ceased
- 2014-03-12 HU HUE18207382A patent/HUE057527T2/hu unknown
- 2014-03-12 AU AU2014244555A patent/AU2014244555B2/en not_active Ceased
- 2014-03-12 HU HUE14719434A patent/HUE041544T2/hu unknown
- 2014-03-12 PT PT182073825T patent/PT3527563T/pt unknown
- 2014-03-12 LT LTEP18207382.5T patent/LT3527563T/lt unknown
- 2014-03-12 RS RS20190243A patent/RS58374B1/sr unknown
- 2014-03-12 JP JP2016501636A patent/JP6360878B2/ja active Active
- 2014-03-12 BR BR112015021888-1A patent/BR112015021888B1/pt active IP Right Grant
- 2014-03-12 HR HRP20211855TT patent/HRP20211855T1/hr unknown
- 2014-03-12 RS RS20211467A patent/RS62649B1/sr unknown
- 2014-03-12 EP EP14719434.4A patent/EP2970218B8/en active Active
- 2014-03-12 ES ES14719434T patent/ES2711839T3/es active Active
- 2014-03-12 PL PL18207382T patent/PL3527563T3/pl unknown
- 2014-03-12 ES ES18207382T patent/ES2900061T3/es active Active
- 2014-03-12 RU RU2015143211A patent/RU2676259C2/ru active
- 2014-03-12 CA CA2904641A patent/CA2904641C/en active Active
- 2014-03-12 SM SM20210687T patent/SMT202100687T1/it unknown
- 2014-03-12 KR KR1020157028350A patent/KR102216284B1/ko not_active Expired - Fee Related
- 2014-03-12 DK DK14719434.4T patent/DK2970218T3/en active
- 2014-03-12 HR HRP20190373TT patent/HRP20190373T1/hr unknown
- 2014-03-12 SM SM20190107T patent/SMT201900107T1/it unknown
- 2014-03-12 TR TR2019/01886T patent/TR201901886T4/tr unknown
- 2014-03-12 PT PT14719434T patent/PT2970218T/pt unknown
- 2014-03-12 DK DK18207382.5T patent/DK3527563T3/da active
- 2014-03-12 SG SG11201507203RA patent/SG11201507203RA/en unknown
- 2014-03-12 ME MEP-2019-55A patent/ME03336B/me unknown
- 2014-03-12 EP EP18207382.5A patent/EP3527563B1/en active Active
- 2014-03-12 US US14/205,657 patent/US9340557B2/en active Active
- 2014-03-12 CN CN201710472183.0A patent/CN107200749B/zh active Active
- 2014-03-12 PL PL14719434T patent/PL2970218T3/pl unknown
- 2014-03-12 MX MX2015012502A patent/MX365294B/es active IP Right Grant
- 2014-03-12 SI SI201431104T patent/SI2970218T1/sl unknown
- 2014-03-12 LT LTEP14719434.4T patent/LT2970218T/lt unknown
- 2014-03-12 CN CN201480025199.1A patent/CN105246883B/zh active Active
-
2015
- 2015-09-08 IL IL241330A patent/IL241330B/en active IP Right Grant
-
2016
- 2016-04-20 US US15/133,378 patent/US9987284B2/en active Active
- 2016-05-06 US US15/148,229 patent/US20160354381A1/en not_active Abandoned
-
2017
- 2017-07-25 US US15/659,306 patent/US10258627B2/en active Active
-
2018
- 2018-04-27 US US15/965,489 patent/US20180311254A1/en not_active Abandoned
- 2018-05-14 JP JP2018092924A patent/JP2018135389A/ja not_active Withdrawn
- 2018-09-27 AU AU2018236800A patent/AU2018236800B2/en not_active Ceased
-
2019
- 2019-02-20 CY CY20191100217T patent/CY1121360T1/el unknown
- 2019-02-21 US US16/282,083 patent/US10786512B2/en active Active
- 2019-04-01 US US16/372,080 patent/US10973830B2/en active Active
-
2020
- 2020-09-17 US US17/023,597 patent/US11813267B2/en active Active
-
2021
- 2021-02-09 US US17/171,061 patent/US20210236505A1/en not_active Abandoned
- 2021-12-01 CY CY20211101051T patent/CY1125436T1/el unknown
-
2023
- 2023-02-27 US US18/175,515 patent/US12251387B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516706A5 (enExample) | ||
| JP6218260B2 (ja) | Ｊａｋ阻害剤としてのアミノピリミジニル化合物 | |
| JP6750806B2 (ja) | Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体 | |
| KR101985984B1 (ko) | 키나아제 저해제로서의 벤조니트릴 유도체 | |
| KR102128671B1 (ko) | 피라졸로[1,5-a]피라진-4-일 유도체 | |
| CA2895239C (en) | Compounds and methods for kinase modulation, and indications therefor | |
| DK2017278T3 (en) | DIHYDROPYRAZOLOPYRIMIDINON DERIVATIVES | |
| KR20230137368A (ko) | 암을 치료 및/또는 예방하기 위한 sos1 저해제들의약학적 조합물 | |
| EP3423451A1 (en) | Inhibitors of wdr5 protein-protein binding | |
| JP2009507032A (ja) | 新規なイミダゾ系複素環 | |
| EP2593451A2 (en) | Substituted imidazo[1,2-a]pyrimidines and -pyridines | |
| WO2019224773A1 (en) | Heterocyclic amides as rip1 kinase inhibitors | |
| WO2012139930A1 (en) | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | |
| CA2918813A1 (en) | Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinases | |
| JP2021529815A (ja) | 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼ阻害剤 | |
| WO2021146192A1 (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
| AU2012310168A1 (en) | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase | |
| JP2023021277A (ja) | アザインドリルピリドンおよびジアザインドリルピリドン化合物 | |
| JP2018513153A (ja) | Ｐｄｅ１０インヒビターならびに関連する組成物および方法 | |
| WO2021113633A1 (en) | Fused tricyclic heterocyclic compounds as inhibitors of pikfyve kinase useful for the treatment of neurological diseases | |
| KR20200078465A (ko) | 신규한 티아졸 유도체 및 이의 약학적으로 허용가능한 염 | |
| JP2019515939A (ja) | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 | |
| WO2025049774A1 (en) | (e)-2-(benzylamino)-n-(3-(methylsulfonyl)allyl)-benzamide derivatives and similar compounds as jak1 inhibitors for the treatment of inflammatory diseases, autoimmune diseases or cancer | |
| KR20230171440A (ko) | 약학적 화합물 | |
| EA048604B1 (ru) | ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ С N-ПРИСОЕДИНЕННЫМИ ЦИКЛИЧЕСКИМИ ЗАМЕСТИТЕЛЯМИ В КАЧЕСТВЕ ИНГИБИТОРОВ cGAS |